Government-Owned Inventions; Availability for Licensing, 60408-60409 [2017-27417]
Download as PDF
<![CDATA[
60408
Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Notices
collection techniques or other forms of
information technology.
Proposed Collection Title: Fellowship
Program and Summer Student
Applications 0925–0716, Exp., date 5/
31/2018, Extension, National Cancer
Institute (NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: This is a request for approval
of an ‘‘Extension’’ for three years. The
National Cancer Institute, Division of
Cancer Epidemiology and Genetics
(DCEG) Office of Education administers
a variety of programs and initiatives to
recruit pre-college through post-doctoral
educational level individuals into the
Intramural Research Program to
facilitate their development into future
biomedical scientists. DCEG trains post-
doctoral, doctoral candidates, graduate
and baccalaureate students, through full
time fellowships, summer fellowships,
and internships in preparation for
research careers in cancer epidemiology
and genetics. The proposed information
collection involves brief online
applications completed by applicants to
the full time and the summer fellowship
programs. Full-time fellowships
include: Full-time Equivalents (FTE)
and non-FTE fellowships for US
citizens, permanent residents and
international fellows. These
applications are essential to the
administration of these training
programs as they enable OE to
determine the eligibility and quality of
potential awardees; to assess their
potential as future scientists; to
determine where mutual research
interests exist; and to make decisions
regarding which applicants will be
proposed and approved for traineeship
awards. In each case, completing the
application is voluntary, but in order to
receive due consideration, the
prospective trainee is encouraged to
complete all relevant fields. The
information is for internal use to make
decisions about prospective fellows and
students that could benefit from the
DCEG program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
218 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Number of
responses per
respondent
Average
time per
response
(in hours)
Total
annual
burden
hour
Full-time Fellows ..............................................................................................
Summer Students ............................................................................................
150
430
1
1
30/60
20/60
75
143
Total ..........................................................................................................
580
580
........................
218
Dated: December 4, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
[FR Doc. 2017–27415 Filed 12–19–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Natalie Greco, 301–761–7898;
Natalie.Greco@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:36 Dec 19, 2017
Jkt 244001
Enhanced Tissue Clearing Solution,
Clearing-Enhanced 3D (Ce3D),
Compatible With Advanced
Fluorescence Microscopy Imaging
Description of Technology: NIH
immunologists have created a solution,
Clearing-enhanced 3D (Ce3D), that can
be used to make entire organs extremely
transparent. This allows the tissue to be
imaged using advanced fluorescence
microscopy techniques. Unlike current
tissue clearing solutions, the Ce3D
tissue clearing solution is robustly
compatible with a variety of staining
methods, and preserves tissue
morphology and reporter fluorescence.
Ce3D enabled microscopy provides
unprecedented insight into the spatial
organization of cells within intact
organs. Further, when Ce3D enabled
microscopy is coupled with multiplexed
staining and a newly developed analysis
pipeline, investigators are able to
extensively characterize densely packed
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
cells in situ, providing advantages to
phenotyping cells with flow cytometric
techniques.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Research reagent—can be applied to
a variety of biological disciplines.
• Diagnostic medical imaging
reagent—characterization of disease
state/condition.
Competitive Advantages:
• Simple, quick and inexpensive
procedure that has been extensively
validated.
• Generates excellent tissue
transparency, resulting in high quality
images.
• Compatible with highly
multiplexed staining/labeling
techniques, including antibody-based
methods, fluorescently tagged reporter
proteins, and RNA–FISH.
• Fluorescence is maintained in
diverse fluorescent proteins and
fluorophores.
• Enables quantitative analysis of
tissue composition and cellular
distribution in whole organs, and has
advantages over flow cytometric
techniques.
Development Stage:
E:\FR\FM\20DEN1.SGM
20DEN1
60409
Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Notices
• Prototype.
Inventors: Ronald N. Germain,
Michael Y. Gerner, Weizhe Li (All from
NIAID).
Publications: Li W, et al. (2017)—
Multiplex, quantitative cellular analysis
in large tissue volumes with clearingenhanced 3D microscopy (Ce3D) [PMID:
28808033—PMCID: PMC5584454].
Intellectual Property: PCT Patent
Application—PCT/US2017/049133,
HHS Reference No. E–168–2016.
Licensing Contact: Dr. Natalie Greco,
301–761–7898; Natalie.Greco@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize tissue-clearing
technologies. For collaboration
opportunities, please contact Dr. Natalie
Greco, 301–761–7898; Natalie.Greco@
nih.gov.
Dated: December 13, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–27417 Filed 12–19–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2017–0466]
Removal of Conditions of Entry for
Certain Vessels Arriving to the United
ˆ
States From Two Port Facilities in Cote
d’Ivoire
Coast Guard, DHS.
Notice.
AGENCY:
ACTION:
The Coast Guard announces
that it is modifying the conditions of
entry for vessels arriving to the United
ˆ
States from Cote d’Ivoire by adding an
exception to the conditions of entry for
ˆ
two facilities in the Republic of Cote
d’Ivoire.
DATES: The policy takes effect January 3,
2018.
FOR FURTHER INFORMATION CONTACT: For
information about this document call or
email Juliet Hudson, International Port
Security Evaluation Division, United
States Coast Guard, telephone 202–372–
1173.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Discussion
The authority for this notice is 5
U.S.C. 552(a), 46 U.S.C. 70110, and
Department of Homeland Security
Delegation No. 0170.1(II)(97.f). Section
70110(a) provides that the Secretary of
Homeland Security may impose
conditions of entry into the United
States from ports that are not
maintaining effective anti-terrorism
measures. Section 70110(d) provides
that these conditions may be removed
upon Secretary’s determination that the
measures are maintained. The Secretary
delegated the authority to carry out the
provisions of these sections to the Coast
Guard. Section 552(a)(1)(E) requires an
agency to provide a Federal Register
notice to the public in regards to any
amendment, revision or repeal of a rule
adopted as authorized by law. The
Regulatory Docket for this Notice
(USCG–2017–0466) contains previous
notices imposing or removing
conditions of entry on vessels arriving
from certain countries.
On May 27, 2011, the Coast Guard
determined that ports in the Republic of
ˆ
Cote d’Ivoire did not maintain effective
ˆ
anti-terrorism measures and that Cote
d’Ivoire’s designated authority’s
oversight, access control and cargo
control remained deficient (76 FR
30954). However, since 2014 the Coast
Guard has assessed and found that the
port facilities listed in Table 1 do have
effective anti-terrorism measures. As
such, port facilities listed in Table 1 are
exempted from the conditions of entry
previously imposed.
TABLE 1—EXEMPTED PORT FACILITIES
Port
Carena Shipyard ..................
Terminal A Containers,
Abidjan.
IMO port No.
CIABJ–0004
CIABJ–0015
Accordingly, beginning January 3,
2018, the conditions of entry shown in
Table 2 below will apply to any vessel
ˆ
that visited a non-exempted Cote
d’Ivoire port facility in its last five port
calls.
ˆ
TABLE 2—CONDITIONS OF ENTRY FOR VESSELS VISITING COTE D’IVOIRE’S PORTS NOT LISTED IN TABLE 1
No.
1 ...........................................
2 ...........................................
sradovich on DSK3GMQ082PROD with NOTICES
3 ...........................................
4
5
6
7
...........................................
...........................................
...........................................
...........................................
VerDate Sep<11>2014
21:36 Dec 19, 2017
Each vessel must:
Implement measures per the vessel’s security plan equivalent to Security Level 2 while in a port in the Republic
ˆ
of Cote d’Ivoire. As defined in the ISPS Code and incorporated herein, ‘‘Security Level 2’’ refers to the ‘‘level
for which appropriate additional protective security measures shall be maintained for a period of time as a result of heightened risk of a security incident.’’
Ensure that each access point to the vessel is guarded and that the guards have total visibility of the exterior
ˆ
(both landside and waterside) of the vessel while the vessel is in ports in the Republic of Cote d’Ivoire.
Guards may be provided by the vessel’s crew; however, additional crewmembers should be placed on the vessel
if necessary to ensure that limits on maximum hours of work are not exceeded and/or minimum hours of rest
are met, or provided by outside security forces approved by the vessel’s master and Company Security Officer.
As defined in the ISPS Code and incorporated herein, ‘‘Company Security Officer’’ refers to the ‘‘person designated by the Company for ensuring that a ship security assessment is carried out; that a ship security plan is
developed, submitted for approval, and thereafter implemented and maintained and for liaison with port facility
security officers and the ship security officer.’’
ˆ
Attempt to execute a Declaration of Security while in a port in the Republic of Cote d’Ivoire.
Log all security actions in the vessel’s log; and
Report actions taken to the cognizant Coast Guard Captain of the Port (COTP) prior to arrival into U.S. waters.
In addition, based on the findings of the Coast Guard boarding or examination, the vessel may be required to ensure that each access point to the vessel is guarded by armed, private security guards and that they have total
visibility of the exterior (both landside and waterside) of the vessel while in U.S. ports. The number and position
of the guards has to be acceptable to the cognizant COTP prior to the vessel’s arrival.
Jkt 244001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\20DEN1.SGM
20DEN1
]]>Agencies
[Federal Register Volume 82, Number 243 (Wednesday, December 20, 2017)]
[Notices]
[Pages 60408-60409]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-27417]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dr. Natalie Greco, 301-761-7898;
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D),
Compatible With Advanced Fluorescence Microscopy Imaging
Description of Technology: NIH immunologists have created a
solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire
organs extremely transparent. This allows the tissue to be imaged using
advanced fluorescence microscopy techniques. Unlike current tissue
clearing solutions, the Ce3D tissue clearing solution is robustly
compatible with a variety of staining methods, and preserves tissue
morphology and reporter fluorescence. Ce3D enabled microscopy provides
unprecedented insight into the spatial organization of cells within
intact organs. Further, when Ce3D enabled microscopy is coupled with
multiplexed staining and a newly developed analysis pipeline,
investigators are able to extensively characterize densely packed cells
in situ, providing advantages to phenotyping cells with flow cytometric
techniques.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Research reagent--can be applied to a variety of
biological disciplines.
Diagnostic medical imaging reagent--characterization of
disease state/condition.
Competitive Advantages:
Simple, quick and inexpensive procedure that has been
extensively validated.
Generates excellent tissue transparency, resulting in high
quality images.
Compatible with highly multiplexed staining/labeling
techniques, including antibody-based methods, fluorescently tagged
reporter proteins, and RNA-FISH.
Fluorescence is maintained in diverse fluorescent proteins
and fluorophores.
Enables quantitative analysis of tissue composition and
cellular distribution in whole organs, and has advantages over flow
cytometric techniques.
Development Stage:
[[Page 60409]]
Prototype.
Inventors: Ronald N. Germain, Michael Y. Gerner, Weizhe Li (All
from NIAID).
Publications: Li W, et al. (2017)--Multiplex, quantitative cellular
analysis in large tissue volumes with clearing-enhanced 3D microscopy
(Ce3D) [PMID: 28808033--PMCID: PMC5584454].
Intellectual Property: PCT Patent Application--PCT/US2017/049133,
HHS Reference No. E-168-2016.
Licensing Contact: Dr. Natalie Greco, 301-761-7898;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize tissue-clearing technologies. For
collaboration opportunities, please contact Dr. Natalie Greco, 301-761-
7898; [email protected].
Dated: December 13, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-27417 Filed 12-19-17; 8:45 am]
BILLING CODE 4140-01-P
